 | Up a level |
Tang, Bo-Hao and Guan, Zheng and Allegaert, Karel and Wu, Yue-E. and Manolis, Efthymios and Leroux, Stephanie and Yao, Bu-Fan and Shi, Hai-Yan and Li, Xiao and Huang, Xin and Wang, Wen-Qi and Shen, A. -Dong and Wang, Xiao-Ling and Wang, Tian-You and Kou, Chen and Xu, Hai-Yan and Zhou, Yue and Zheng, Yi and Hao, Guo-Xiang and Xu, Bao-Ping and Thomson, Alison H. and Capparelli, Edmund V. and Biran, Valerie and Simon, Nicolas and Meibohm, Bernd and Lo, Yoke-Lin and Marques, Remedios and Peris, Jose-Esteban and Lutsar, Irja and Saito, Jumpei and Burggraaf, Jacobus and Jacqz-Aigrain, Evelyne and van den Anker, John and Zhao, Wei (2021) Drug clearance in neonates: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction. Clinical Pharmacokinetics, 60 (11). pp. 1435-1448. ISSN 0312-5963, DOI https://doi.org/10.1007/s40262-021-01033-x.
van der Aart-van der Beek, Annemarie B. and Koomen, Jeroen V. and Dekkers, Claire C.J. and Barbour, Sean J. and Boulton, David W. and Gansevoort, Ron T. and Greasley, Peter J. and Abdul Gafor, Abdul Halim and Laverman, Gozewijn D. and Li, Qiang and Lim, Soo Kun and Stevens, Jasper and Vervloet, Marc G. and Singh, Sunita and Cattran, Daniel C. and Reich, Heather N. and Cherney, David Z.I. and Heerspink, Hiddo J.L. (2021) Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. Clinical Pharmacokinetics, 60 (4). pp. 517-525. ISSN 0312-5963, DOI https://doi.org/10.1007/s40262-020-00956-1.
van der van der Beek, Annemarie B. and Koomen, Jeroen V. and Dekkers, Claire C. J. and Barbour, Sean J. and Boulton, David W. and Gansevoort, Ron T. and Greasley, Peter J. and Abdul Gafor, Abdul Halim and Laverman, Gozewijn D. and Li, Qiang and Lim, Soo Kun and Stevens, Jasper and Vervloet, Marc G. and Singh, Sunita and Cattran, Daniel C. and Reich, Heather N. and Cherney, David Z. I. and Heerspink, Hiddo J. L. (2021) Evaluation of the pharmacokinetics and exposure-response relationship of dapagliflozin in patients without diabetes and with chronic kidney disease. Clinical Pharmacokinetics, 60 (4). pp. 517-525. ISSN 0312-5963, DOI https://doi.org/10.1007/s40262-020-00956-1.
